Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease

D. Ramirez-Montealegre, S. Chattopadhyay, T. M. Curran, C. Wasserfall, L. Pritchard, D. Schatz, J. Petitto, D. Hopkins, J. X. She, P. G. Rothberg, M. Atkinson, David A. Pearce

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

The pathogenic mechanisms underlying Batten disease are unclear. Patients uniformly possess autoantibodies against glutamic acid decarboxylase (GAD) that are predominantly reactive with a region of GAD (amino acids 1 to 20) distinct from subjects with autoimmune type 1 diabetes or stiff-person syndrome. Batten patients did not possess autoantibodies against other type 1 diabetes-associated autoantigens and human leukocyte antigen genotypes revealed no specific associations with this disease.

Original languageEnglish (US)
Pages (from-to)743-745
Number of pages3
JournalNeurology
Volume64
Issue number4
DOIs
StatePublished - Feb 22 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease'. Together they form a unique fingerprint.

  • Cite this

    Ramirez-Montealegre, D., Chattopadhyay, S., Curran, T. M., Wasserfall, C., Pritchard, L., Schatz, D., Petitto, J., Hopkins, D., She, J. X., Rothberg, P. G., Atkinson, M., & Pearce, D. A. (2005). Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology, 64(4), 743-745. https://doi.org/10.1212/01.WNL.0000151973.08426.7E